MedDataX Logo

Vascular Cardiotoxicity of Ponatinib

NCT03930394 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2019-06-07

No results posted yet for this study

Summary

Pre-clinical studies suggest that the third generation tyrosine kinase inhibitor ponatinib can result in microvascular angiopathy and acceleration of atherosclerosis. This study is intended to examine for myocardial microvascular angiopathy and changes in carotid plaque in patients receiving ponatinib as part of their clinical care.

Conditions

  • Cardiotoxicity

Interventions

DIAGNOSTIC_TEST

Contrast ultrasound perfusion imaging

Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2021-05-01
Completion
2022-05-01

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03930394 on ClinicalTrials.gov